Cadrenal Therapeutics, Inc. CVKD
1.15
(0.05)
(4.17%)
as of 25 Sep
- Market cap
- $4.3M
- P/E
- 0.0×
Follow CVKD
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Current Ratio |
3.73 | 2.68 | 2.72 | 3.02 |
+8 more quarters Free account |
Net Debt/EBITDA |
0.72 | 0.92 | 1.31 | 1.41 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.67 | 1.20 | 0.85 | 0.88 | |
Capex/Depreciation |
2.80 | 0.00 | 0.00 | (4.50) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.77) | (1.25) | (1.29) | (1.15) | |
Cash per Share |
0.82 | 0.96 | 2.01 | 1.89 | |
Shareholders Equity per Share |
1.40 | 0.75 | 1.37 | 1.34 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.40 | 0.75 | 1.37 | 1.34 | |
Free Cash Flow |
(2.23) | (3.00) | (2.57) | (2.36) | |
Working Capital |
4.09 | 1.79 | 2.73 | 2.73 | |
Capital Expenditures |
0.00 | — | 0.00 | 0.00 | |
Net Current Asset Value |
4.09 | 1.79 | 2.73 | 2.73 | |
| Other line items | |||||
Quick Ratio |
3.39 | 2.17 | 2.53 | 2.86 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.77) | (1.25) | (1.29) | (1.15) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Receivables |
1.35 | 0.02 | 0.02 | 0.03 | |
Average Payables |
0.88 | 1.05 | 1.08 | 0.56 | |
Average Assets |
5.78 | 5.41 | 7.23 | 4.38 | |
Average Common Equity |
4.20 | 3.96 | 5.09 | 3.07 | |
Capex to Sales |
0.00 | — | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates